Connect your AI

ImmunityBio, Inc. IBRX Other Working Capital

Other Working Capital at other companies

Bristol-Myers SquibbBMY

$1.64B+54.5%

IncyteINCY

-$12.77M-141%

ExelixisEXEL

$2.02M-57.8%

Nuvalent, Inc.NUVL

-$120K-275%

Kymera TherapeuticsKYMR

——

Protagonist TherapeuticsPTGX

——

Segments

By segment

Reportable Segment$13.87M+2.5%

Other financials

Income statement

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherOperatingActivitiesCashFlowStatement.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ImmunityBio, Inc.'s other working capital?: ImmunityBio, Inc. (IBRX) reported other working capital of $16K in Q1 2026.
How has ImmunityBio, Inc.'s other working capital changed year-over-year?: ImmunityBio, Inc.'s other working capital decreased by 93.4% year-over-year, from $243K to $16K.
What does other working capital mean?: Net change in working capital items not separately classified — a residual balancing item.